Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Taxotere is the first drug to demonstrate a survival benefit in hormone refractory patients, FDA said. Aventis is investigating docetaxel as first-line therapy.